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ship between TNF- therapy and autoantibodies (anti-dsDNAvailable online xxx
ntroduction
herapy for RA has improved rapidly since the advent
f biologics. However, although biologics have a greater
ffect compared to that with conventional disease modifying
ntirheumatic drugs (DMARDs), the cost of these newer ther-
pies remains extremely high.1 Patients in whom biologics
re effective have increased employment opportunities due to
educed disease activity, meaning that the cost-effectiveness
f the treatment is valid. However, in cases where the admin-Please cite this article in press as: Suzuki S, et al. Hepcidin-25 give
in rheumatoid arthritis – relationship between disease activity of
http://dx.doi.org/10.1016/j.rbre.2016.09.004
stration of biologics is not associated with a response, disease
ctivity during the period of treatment and the progres-
ion of joint damage place an incalculable burden on both
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reativecommons.org/licenses/by-nc-nd/4.0/).patients and the entire medical system. For this reason,
the identiﬁcation of factors that can predict the effective-
ness of biologics in each patient, before administration, is a
critical issue; tailor-made therapies using single nucleotide
polymorphisms (SNPs) are currently being investigated. In
Japan, biologics currently available for use in RA include those
that target tumor necrosis factor (TNF)- (inﬂiximab, etan-
ercept, adalimumab, golimumab, and certolizumab pegol),
tocilizumab (TCZ), which targets IL-6, and abatacept, which
targets CD80/86. We  have previously reported on the relation-s an indication of the therapeutic effectiveness of tocilizumab
 rheumatoid arthritis and anemia. Rev Bras Reumatol. 2016.
antibodies and anti-SS-A antibodies) in patients with insufﬁ-
cient responses.2 In the present study, we  examined predictive
factors for the therapeutic effect of biologics, while focusing
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Table 1 – Patient characteristics.
Patients Sex Age
(y.o)
Duration
(years)
Hb  (g/dL) CRP
(mg/dL)
MMP3
(ng/mL)
CDAI  (CDAI at 24
weeks later)
MTX
(mg/w)
PSL
(mg/day)
Previous
biologics
1 F 78 4 13.0 0.8 96 8.0 (6.2) 8 4 ETN
2 M 58 2 13.6 2.3 258 34.2 (24.9) 7.5 10 –
3 F 73 3 11.4 5.1 243 31.6 (29.7) – – –
4 F 51 4 11.1 2.7 170 26 .0(1.0) 10 10 INF
5 F 61 7 12.5 0.6 284 16.3 (4.0) 8 7.5 –
6 F 46 7 13.3 1.8 176 14.3 (10.9) 6 8 INF
7 F 49 13 13.6 0.2 – 19.5 (1.1) – – ETN
8 F 73 21 10.0 0.1 150 16.0 (24.0) 10 7.5 –
9 F 60 20 12.4 3.2 714 24.5 (40.0) 6 4 INF
10 F 39 6 10.1 4.2 403 29.2 (8.0) 8 4 INF
teinaHb, hemoglobin; CRP, C-reactive protein; MMP3, matrix metallopro
prednisolone; INF, inﬂiximab; ETN, etanercept.
on the effect of TCZ in ameliorating anemia of chronic
inﬂammation, via direct inhibition of IL-6 receptor-mediated
signaling.3 Hepcidin-25, a major cause of anemia of chronic
inﬂammation,4 was measured in the serum of RA patients.
We compared serum hepcidin-25 levels with clinical data and
cytokine levels, to examine whether hepcidin-25 could act as
a predictive factor for the effectiveness of TCZ.
Materials  and  methods
Patients
The 10 patients selected for inclusion in the study had previ-
ously been admitted to the Sasaki Institute Kyoundo Hospital
Division of Internal Medicine and Rheumatology between
September 2008 and September 2010. Patients had com-
menced TCZ therapy during this period, and were either naive
to biologics or had changed from other biologics to TCZ.
All RA patients met  the American College of Rheumatology
(ACR) 1987 revised criteria for the classiﬁcation of rheumatoid
arthritis.5 Based on the Declaration of Helsinki and the guide-
lines of the institutional review board of Kyoundo Hospital,
written consent was obtained from all patients prior to the
start of the study. The characteristics of the 10 patients are
shown in Table 1.
Methods
Hepcidin-25 and IL-6 levels were measured before introduc-
tion of TCZ and 3 months after introduction. The serum
samples were stored at −80 ◦C. Serum hepcidin-25, which is
thought to be the form of hepcidin with the greatest bioactiv-
ity, was measured using an enzyme-linked immunosorbent
assay (ELISA) (Hepcidin-25 EIA Kit; BACHEM, Bubendorf,
Switzerland). Serum IL-6 was also measured using ELISA
(Human IL-6 Quantikine ELISA Kit; R&D Systems, Minneapo-
lis, MN, USA). Both hepcidin-25 and IL-6 were measured using
the Sandwich ELISA protocol. Test results from routine testsPlease cite this article in press as: Suzuki S, et al. Hepcidin-25 give
in rheumatoid arthritis – relationship between disease activity of
http://dx.doi.org/10.1016/j.rbre.2016.09.004
undertaken during general examination at Kyoundo Hospi-
tal, including serum hemoglobin, C-reactive protein (CRP),
and erythrocyte sedimentation rate (ESR), were also used in
our analysis. RA disease activity was assessed using clinicalse3; CDAI clinical disease activity index; MTX, methotrexate; PSL,
disease activity index (CDAI). Student’s t-test was used for sta-
tistical analysis. A p-value <0.05 was considered statistically
signiﬁcant.
Results
Therapeutic  effectiveness  of  TCZ  in  RA  patients
CDAI for patients prior to and after treatment with TCZ are
shown in Fig. 1A.
Six months after initiation of treatment with TCZ, lower
CDAI were noted in 8 of 10 patients.
Comparison  of  hepcidin-25  levels  in  RA  patients  and
healthy  subjects
In a comparison of serum hepcidin-25 levels in RA patients
before receiving treatment with TCZ and in healthy subjects,
hepcidin-25 levels were signiﬁcantly elevated in RA patients
(Fig. 1B).
Changes  in  hepcidin-25  and  IL-6  levels  in  RA  patients
Serum hepcidin-25 and IL-6 levels in RA patients before
administration of TCZ and 12 weeks (3 months) after admin-
istration are shown in Fig. 1C.
Hepcidin-25
Serum hepcidin-25 levels were high in 8 of 10 patients before
administration of TCZ; in these 8 patients, levels decreased
after treatment with TCZ. However, in the 2 patients that had
comparatively low levels before administration, treatment
with TCZ was associated with an increase in hepcidin-25.
These results reﬂected the effectiveness of TCZ therapy. In the
8 patients who exhibited a decrease in hepcidin-25, TCZ ther-
apy was effective, while in the latter 2 patients, TCZ therapy
was determined to be ineffective.s an indication of the therapeutic effectiveness of tocilizumab
 rheumatoid arthritis and anemia. Rev Bras Reumatol. 2016.
IL-6
It is known that because TCZ is an IL-6 receptor antagonist,
serum IL-6 levels temporarily increase after administration.6
In the present study, levels increased in the majority of
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Fig. 1 – (A) Six months after initiation of treatment with TCZ, CDAI was lower in 8 of 10 patients, and was therefore
considered to be effective. TCZ was found to be ineffective in 2 of 10 patients; (B) in a comparison of serum hepcidin-25
levels in RA patients and healthy subjects, hepcidin-25 levels were  found to be signiﬁcantly elevated in RA patients (p < 0.01);
(C) high levels of serum hepcidin-25 were  observed prior to administration of TCZ, and decreased 3 months after initiation
of treatment. However, 2 of 10 patients had pre-administration levels that were  comparatively low; these levels increased
after treatment with TCZ. These 2 cases were consistent with the 2 patients in whom TCZ was considered to be ineffective 6
months after initiation of treatment. The gray line indicates the same patients as the gray line in (A); (D) we examined
hemoglobin levels 3 months after administration of TCZ. Elevated hemoglobin levels were  noted in 5 of 10 patients. Elevated
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nevels were  observed in 3 of 4 patients in whom anemia was
atients after administration of TCZ; however, a decrease was
oted in 3 patients.
elationship  between  hepcidin-25  and  anemia
e  observed changes in serum hemoglobin levels 3 months
fter the start of TCZ treatment, compared with the pre-
CZ hemoglobin level (Fig. 1D). Hemoglobin levels, a general
ndicator of anemia, increased in 5 of 10 patients after admin-
stration of TCZ. When analysis was limited to those patients
n whom anemia was present prior to receiving treatment (Hb
12 g/dL), most patients showed an increase in hemoglobin
evels.
iscussion
epcidin is a peptide hormone that is produced in the liver.
here are several known isoforms of hepcidin, includingPlease cite this article in press as: Suzuki S, et al. Hepcidin-25 give
in rheumatoid arthritis – relationship between disease activity of
http://dx.doi.org/10.1016/j.rbre.2016.09.004
epcidin-20 and hepcidin-22; hepcidin-25 has the highest
ioactivity and is considered to have a strong relationship
ith iron metabolism.7 Iron taken orally is absorbed by intesti-
al epithelial cells. In the presence of iron deﬁciency, iron issent before receiving treatment (Hb <12 g/dL, dotted line).
released to the peripheral blood. When no deﬁciency of iron
is present, iron is excreted fecally as the epithelial cells are
sloughed off into the intestinal lumen. Most iron absorbed in
the intestinal tract is stored in the liver. A suitable amount
of iron is supplied from the liver to the peripheral blood, for
use in erythrocyte production in the bone marrow. Old eryth-
rocytes are trapped and destroyed in the reticuloendothelial
system, and the iron is taken up by the system, and released
again into the peripheral blood. In the case of chronic inﬂam-
matory diseases such as RA, there is an overproduction of
IL-6. When IL-6 binds to its receptors in the liver, hepcidin-
25 is produced. Hepcidin-25 binds to ferroportin, expressed
in hepatocytes and reticuloendothelial macrophages, leading
to inhibition of intestinal absorption of iron, and inhibi-
tion of iron release from the reticuloendothelial system and
hepatocytes; together these factors result in the develop-
ment of anemia.8,9 Hepcidin expression is up-regulated by
iron and inﬂammation and down-regulated by anemia and
hypoxia.10s an indication of the therapeutic effectiveness of tocilizumab
 rheumatoid arthritis and anemia. Rev Bras Reumatol. 2016.
On the basis of this knowledge, it is considered that RA
patients with high disease activity and high hepcidin-25
levels are especially inﬂuenced by IL-611; TCZ treatment is
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anticipated to be particularly effective in these patients. How-
ever, in the present study TCZ was not effective in 2 cases,
despite the fact that serum IL-6 levels before treatment were
abnormally high; in 1 of these cases serum hepcidin-25 lev-
els were low (Fig. 1C). It has previously been reported that
although anemia of chronic inﬂammation may be present in
RA patients, a low level of hepcidin that is strongly indica-
tive of iron deﬁciency, was also noted.12 In the present
study, marked iron deﬁciency was noted in patients who
had abnormally high serum IL-6 levels with concomitant low
hepcidin-25 levels.
We  concluded that because hepcidin-25 levels decreased
after TCZ administration and improvement in the associated
anemia was noted, TCZ can ameliorate anemia of chronic
inﬂammation.
Patients that had high hepcidin-25 levels before adminis-
tration of TCZ and lower levels 3 months after treatment, were
still evaluated as having had a good response 6 months after
treatment. Based on this, we  consider that hepcidin-25 can
act as a predictive factor for the effectiveness of TCZ treat-
ment. However, caution is needed in determining cases of iron
deﬁciency anemia. Measurement of hepcidin can be easily per-
formed, and the application of hepcidin as a clinical indicator
in RA patients can be expected in the future.
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